Novel Orally-Active Kinase Inhibitor Induces Tumor (Ringworm Treatment)
Novel Orally-Active Kinase Inhibitor Induces Tumor
MSN MoneyCentral - Lead Multi-Target Kinase Inhibitor Presented at ASH Meeting ROCKVILLE, Md., Dec. 11 /PRNewswire-FirstCall/ -- EntreMed, Inc. ENMD , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases
Roche cancer treatment Xeloda reaches primary endpoint in latest Phase
Forbes - BASEL (AFX) - Roche Holding AG said that its latest Phase III study of cancer treatment Xeloda with 627 previously treated patients with advanced colorectal cancer met its primary endpoint of progression-free survival. Study results showed that the
Research Suggests New Treatment Approaches For Glaucoma
Medical News Today - New research from Children's Hospital Boston and the Massachusetts Eye and Ear Infirmary (MEEI) may help explain how glaucoma causes blindness, revealing the chain of cellular and molecular events that ultimately damage the optic nerve, preventing
Data Show Efficacy of Extended Dosing of Aranesp(R) in the Treatment
Forbes - Amgen (NASDAQ: AMGN) today announced data from two studies showing that extended dosing of Aranesp(R) (darbepoetin alfa) is effective in increasing hemoglobin levels to the target level of 11 to 12 g/dL and reducing the need for red blood cell
Psychedelic drug 'hope for OCD'
BBC News - The need for more treatment options and anecdotal reports of OCD patients undergoing periods of remission after using hallucinogens led Moreno and colleagues to give low (8mg), medium (16mg), and high (24mg) doses of psilocybin to nine people who had
UPDATE 1-Nuvelo, Bayer say alfimeprase drug trial fails
Reuters - FRANKFURT, Dec 11 (Reuters) - Nuvelo, Inc. (NUVO.O: Quote , Profile , Research ) and Bayer (BAYG.DE: Quote , Profile , Research ) said on Monday the late clinical trial of blood clot dissolver alfimeprase for treatment of acute peripheral arterial








